This company has been marked as potentially delisted and may not be actively trading.

Nuwellis (CHFS) Competitors

CHFS vs. VRAYQ, VIVE, ELMD, NRXS, and QTI

Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), NeurAxis (NRXS), and QT Imaging (QTI). These companies are all part of the "medical" sector.

How does Nuwellis compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

: ViewRay has a net margin of 0.00% compared to Nuwellis' net margin of -254.26%. ViewRay's return on equity of 0.00% beat Nuwellis' return on equity.
Company Net Margins Return on Equity Return on Assets
ViewRay N/A N/A N/A
Nuwellis -254.26% -173.61% -131.01%
: ViewRay has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
: 15.5% of ViewRay shares are owned by institutional investors. Comparatively, 65.1% of Nuwellis shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 0.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Nuwellis has lower revenue, but higher earnings than ViewRay. Nuwellis is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ViewRay $102.21M 0.00 -$107.33M -$0.31 N/A
Nuwellis $5.51M 1.18 -$18.11M -$279.28 N/A
: In the previous week, ViewRay's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.
Company Overall Sentiment
ViewRay Neutral
Nuwellis Neutral

Company	Net Margins	Return on Equity	Return on Assets
ViewRay	N/A	N/A	N/A
Nuwellis	-254.26%	-173.61%	-131.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ViewRay	$102.21M	0.00	-$107.33M	-$0.31	N/A
Nuwellis	$5.51M	1.18	-$18.11M	-$279.28	N/A

Company	Overall Sentiment
ViewRay	Neutral
Nuwellis	Neutral

Summary

ViewRay beats Nuwellis on 7 of the 10 factors compared between the two stocks.

How does Nuwellis compare to Viveve Medical?

Viveve Medical (NASDAQ:VIVE) and Nuwellis (NASDAQ:CHFS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

: Viveve Medical has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
: Viveve Medical has a net margin of 0.00% compared to Nuwellis' net margin of -254.26%. Viveve Medical's return on equity of 0.00% beat Nuwellis' return on equity.
Company Net Margins Return on Equity Return on Assets
Viveve Medical N/A N/A N/A
Nuwellis -254.26% -173.61% -131.01%
: 65.1% of Nuwellis shares are held by institutional investors. 5.7% of Viveve Medical shares are held by company insiders. Comparatively, 0.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Viveve Medical has higher revenue and earnings than Nuwellis.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viveve Medical $6.83M 0.00 N/A N/A N/A
Nuwellis $5.51M 1.18 -$18.11M -$279.28 N/A
: In the previous week, Viveve Medical's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.
Company Overall Sentiment
Viveve Medical Neutral
Nuwellis Neutral

Company	Net Margins	Return on Equity	Return on Assets
Viveve Medical	N/A	N/A	N/A
Nuwellis	-254.26%	-173.61%	-131.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viveve Medical	$6.83M	0.00	N/A	N/A	N/A
Nuwellis	$5.51M	1.18	-$18.11M	-$279.28	N/A

Company	Overall Sentiment
Viveve Medical	Neutral
Nuwellis	Neutral

Summary

Viveve Medical beats Nuwellis on 6 of the 9 factors compared between the two stocks.

How does Nuwellis compare to Electromed?

Nuwellis (NASDAQ:CHFS) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

: Nuwellis has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
: Electromed has a net margin of 11.34% compared to Nuwellis' net margin of -254.26%. Electromed's return on equity of 15.71% beat Nuwellis' return on equity.
Company Net Margins Return on Equity Return on Assets
Nuwellis -254.26% -173.61% -131.01%
Electromed 11.34% 15.71% 13.37%
: Electromed has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuwellis $5.51M 1.18 -$18.11M -$279.28 N/A
Electromed $68.86M 3.10 $5.15M $1.03 25.06
: Electromed has a consensus price target of $36.67, indicating a potential upside of 42.06%. Given Electromed's stronger consensus rating and higher probable upside, analysts clearly believe Electromed is more favorable than Nuwellis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuwellis
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Electromed
0 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
3.00
: 65.1% of Nuwellis shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 0.6% of Nuwellis shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: In the previous week, Electromed had 2 more articles in the media than Nuwellis. MarketBeat recorded 2 mentions for Electromed and 0 mentions for Nuwellis. Electromed's average media sentiment score of 0.45 beat Nuwellis' score of 0.00 indicating that Electromed is being referred to more favorably in the news media.
Company Overall Sentiment
Nuwellis Neutral
Electromed Neutral

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-254.26%	-173.61%	-131.01%
Electromed	11.34%	15.71%	13.37%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$5.51M	1.18	-$18.11M	-$279.28	N/A
Electromed	$68.86M	3.10	$5.15M	$1.03	25.06

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Overall Sentiment
Nuwellis	Neutral
Electromed	Neutral

Summary

Electromed beats Nuwellis on 15 of the 17 factors compared between the two stocks.

How does Nuwellis compare to NeurAxis?

Nuwellis (NASDAQ:CHFS) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

: NeurAxis has lower revenue, but higher earnings than Nuwellis. NeurAxis is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuwellis $5.51M 1.18 -$18.11M -$279.28 N/A
NeurAxis $3.57M 28.01 -$14.63M -$0.94 N/A
: Nuwellis has a net margin of -254.26% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Nuwellis' return on equity.
Company Net Margins Return on Equity Return on Assets
Nuwellis -254.26% -173.61% -131.01%
NeurAxis -492.76% N/A -641.25%
: Nuwellis has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
: NeurAxis has a consensus price target of $13.00, indicating a potential upside of 49.60%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than Nuwellis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuwellis
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
NeurAxis
0 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
: In the previous week, NeurAxis had 1 more articles in the media than Nuwellis. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Nuwellis. NeurAxis' average media sentiment score of 0.55 beat Nuwellis' score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.
Company Overall Sentiment
Nuwellis Neutral
NeurAxis Positive
: 65.1% of Nuwellis shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 0.6% of Nuwellis shares are held by insiders. Comparatively, 15.2% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$5.51M	1.18	-$18.11M	-$279.28	N/A
NeurAxis	$3.57M	28.01	-$14.63M	-$0.94	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-254.26%	-173.61%	-131.01%
NeurAxis	-492.76%	N/A	-641.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Overall Sentiment
Nuwellis	Neutral
NeurAxis	Positive

Summary

NeurAxis beats Nuwellis on 10 of the 16 factors compared between the two stocks.

How does Nuwellis compare to QT Imaging?

QT Imaging (NASDAQ:QTI) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

: Nuwellis has lower revenue, but higher earnings than QT Imaging. QT Imaging is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
QT Imaging $18.92M 4.32 -$21.08M -$2.19 N/A
Nuwellis $5.51M 1.18 -$18.11M -$279.28 N/A
: QT Imaging has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
: 24.2% of QT Imaging shares are owned by institutional investors. Comparatively, 65.1% of Nuwellis shares are owned by institutional investors. 28.8% of QT Imaging shares are owned by insiders. Comparatively, 0.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: QT Imaging has a net margin of -111.40% compared to Nuwellis' net margin of -254.26%. QT Imaging's return on equity of 0.00% beat Nuwellis' return on equity.
Company Net Margins Return on Equity Return on Assets
QT Imaging -111.40% N/A -115.44%
Nuwellis -254.26% -173.61% -131.01%
: In the previous week, QT Imaging had 1 more articles in the media than Nuwellis. MarketBeat recorded 1 mentions for QT Imaging and 0 mentions for Nuwellis. QT Imaging's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.
Company Overall Sentiment
QT Imaging Neutral
Nuwellis Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QT Imaging
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Nuwellis
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QT Imaging	$18.92M	4.32	-$21.08M	-$2.19	N/A
Nuwellis	$5.51M	1.18	-$18.11M	-$279.28	N/A

Company	Net Margins	Return on Equity	Return on Assets
QT Imaging	-111.40%	N/A	-115.44%
Nuwellis	-254.26%	-173.61%	-131.01%

Company	Overall Sentiment
QT Imaging	Neutral
Nuwellis	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QT Imaging	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

QT Imaging beats Nuwellis on 10 of the 14 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHFS vs. The Competition

Export

Metric	Nuwellis	Electromedical Equipment Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.52M	$64.64M	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	-0.02	4.92	24.91	23.23
Price / Sales	1.18	210.89	504.56	75.49
Price / Cash	N/A	41.36	43.30	53.90
Price / Book	0.08	6.05	9.67	6.69
Net Income	-$18.11M	-$5.50M	$3.55B	$332.64M

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHFS Nuwellis	N/A	$1.08 -4.4%	N/A	N/A	$6.52M	$5.51M	N/A	66
VRAYQ ViewRay	N/A	N/A	N/A	N/A	$18K	$102.21M	N/A	300	High Trading Volume
VIVE Viveve Medical	N/A	$0.00 flat	N/A	N/A	$0.00	$6.83M	N/A	70
ELMD Electromed	2.6491 of 5 stars	$25.71 +2.4%	$36.67 +42.6%	N/A	$212.75M	$68.86M	34.28	160
NRXS NeurAxis	2.7634 of 5 stars	$7.45 +0.1%	$13.00 +74.5%	N/A	$85.71M	$3.57M	N/A	19	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHFS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (CHFS) Competitors